>> Can anything about the progress of the other phase 2 clinical trials be deduced by virtue of the fact that GENR has started the last phase 2 trial? <<
I don’t think so. The real issue is why it took this long (six months) to start the combo trial. I think the delay was probably caused by a combination of the protocol change (adding the 10mg dose) and supply constraints.
Market Data 
Markets 
AI
